Czechia may receive 370,000 doses of newly approved Covid vaccine Nuvaxovid in January

The Czech Republic should receive 370,000 doses of the coronavirus vaccine Nuvaxovid, approved for use in the EU on Monday by the European Medicines Agency, as early as next month.

Nuvaxovid, a protein-based vaccine made by Novavax, is now the fifth accepted for use within the EU. It is administered in two doses at an interval of three weeks.

Laboratory tests indicate it has a 90% efficacy against the first COVID-19 strain, but its effectiveness against the Delta and Omicron strains is unknown.